Home » Stocks » DAWN

Day One Biopharmaceuticals, Inc. (DAWN)

Stock Price: $20.35 USD -0.90 (-4.24%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $20.20 -0.15 (-0.74%) Jun 22, 4:48 PM
Market Cap 1.23B
Revenue (ttm) n/a
Net Income (ttm) -57.95M
Shares Out 60.34M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $20.35
Previous Close $21.25
Change ($) -0.90
Change (%) -4.24%
Day's Open 21.60
Day's Range 19.88 - 21.73
Day's Volume 62,896
52-Week Range 17.19 - 27.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for p...

1 day ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing tar...

3 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targ...

3 weeks ago - GlobeNewsWire

Day One Biopharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About DAWN

Day One is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, we focus our clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. Our lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. ... [Read more...]

Industry
Biotechnology
IPO Date
May 27, 2021
CEO
Jeremy Bender, Ph.D., M.B.A.
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
DAWN
Full Company Profile

Financial Performance

Financial Statements